Consolidated Q2 sales total ₹4,396 crore
India remains the largest market
Watch: Track organic demand
Home / Research / Godrej Consumer Products Limited
Consolidated Q2 sales total ₹4,396 crore
https://www.bseindia.com/xml-data/corpfiling/AttachLive/8bf1e6fa-d1b4-422f-bf06-7cdd37877e69.pdf
https://www.bseindia.com/xml-data/corpfiling/AttachLive/8bf1e6fa-d1b4-422f-bf06-7cdd37877e69.pdf
https://www.bseindia.com/xml-data/corpfiling/AttachLive/8bf1e6fa-d1b4-422f-bf06-7cdd37877e69.pdf
https://www.bseindia.com/xml-data/corpfiling/AttachLive/8bf1e6fa-d1b4-422f-bf06-7cdd37877e69.pdf
India remains the largest market
Watch: Track organic demand
Currency adds to reported growth
Watch: Compare constant currency
Underlying growth is lower than headline
Watch: Monitor currency-adjusted demand
Price and currency also affect sales
Watch: Track next quarter
Godrej Consumer Products (GODREJCP) | Q2 FY27 | Quarter ended 30 September 2026 | Consolidated results, with standalone and geography metrics separately labelled
Investment stance: WATCH. Godrej Consumer Products grew Q2 sales by 19% and reported net profit by 14%, helped by healthy underlying demand in India, Indonesia and Africa. But EBITDA grew only 12%, showing that commodity costs and investment in the business absorbed part of the sales growth. The investment case depends on sustained volume growth and a recovery in operating margins, rather than price-led sales alone. [S1][S2]
| Q2 FY27 measure | Value | Basis |
|---|---|---|
| Consolidated net sales | ₹4,396 crore | Up 19% year on year |
| Consolidated underlying volume growth | 8% | Management measure |
| Consolidated constant-currency sales growth | 15% | Excludes currency translation |
| Consolidated EBITDA growth | 12% | Year on year |
| Consolidated operating EBITDA margin | 18.7% | Presentation's adjusted segment-margin basis |
| Reported consolidated net profit | ₹523 crore | Versus ₹459 crore |
| Net profit without exceptional/one-off items | ₹532 crore | Versus ₹487 crore |
| Standalone sales | ₹2,631 crore | Up 13% year on year |
The reported profit and profit without exceptional items are not interchangeable. The presentation reconciles ₹523 crore reported profit to ₹532 crore excluding selected items, compared with ₹459 crore and ₹487 crore respectively a year earlier. Its EBITDA margin presentation adjusts business support charges, royalty and technical fees for geographic comparability. [S2]
Six decision takeaways
What to watch next: India's home-care demand and pricing, Indonesia volume momentum, Africa's currency-adjusted performance and how quickly margin pressure from commodities eases. No share-price target is assigned without a current market price and comparable valuation inputs.
Godrej Consumer Products sells household and personal-care products across India and international markets. Its businesses include home care, personal care and country-specific consumer brands. This is a branded consumer business: pricing power, distribution reach, product relevance and advertising efficiency determine whether revenue growth becomes sustainable profit. [S1][S2]
The most attractive feature of the Q2 result is the combination of underlying volume growth and broad geographic participation. Sales growth can be misleading when driven by price increases or currency translation alone; 8% consolidated volume growth suggests a meaningful increase in product demand. But the gap between 19% revenue growth and 12% EBITDA growth shows that not all incremental sales retained their former margin. [S2]
Investors should value the domestic franchise and international businesses on their respective earnings durability. India's consumer categories are exposed to monsoon, rural demand and competitive pricing. International businesses add growth but also currency and local execution risks. The presentation gives enough evidence to compare these engines without assuming they all have the same margin. [S1][S2]
Decision tests
The group reported ₹4,396 crore Q2 sales and 19% year-on-year growth. Constant-currency growth was 15%, while underlying volume growth was 8%. EBITDA grew 12%. These measures tell different parts of the story: volumes reflect consumer demand, constant-currency sales reflect business growth excluding translation, and EBITDA captures operating earnings after business costs. [S1][S2]
The presentation gives a consolidated operating EBITDA margin of 18.7% after specified adjustments for business support charges, royalty and technical fees. Standalone India was 21.0%, Indonesia 19.3%, Africa/USA/Middle East 15.0%, and Latin America/Others 0.9%. These geography margins should not be averaged without revenue weights or substituted for statutory consolidated profit. [S2]
Reported net profit increased from ₹459 crore to ₹523 crore. The company's reconciliation adds a net ₹9 crore of exceptional and one-off adjustments to Q2 FY27 reported profit to reach ₹532 crore. The adjustments include negative ₹11 crore of restructuring-cost adjustment and positive ₹20 crore relating to acquisition costs and other items, including litigation. For Q2 FY26, reported ₹459 crore becomes ₹487 crore after an ₹8 crore restructuring adjustment and ₹20 crore other adjustment. [S2]
The acquisition-related ₹20 crore item includes a change in fair valuation of contingent consideration for the Muuchstac brand following higher revenue than previously expected. This is an accounting adjustment tied to acquisition terms, not an additional ₹20 crore of consumer sales. The distinction matters when comparing recurring profitability. [S2]
Financial interpretation
Standalone India generated ₹2,631 crore sales, up 13% with 7% underlying volume growth. Management estimated that a trade-inventory correction reduced the quarter's growth by about 150 basis points (1.5 percentage points). That correction reflects distributors carrying healthier inventory levels, rather than a simple change in final consumer demand. It can temporarily affect shipments even if retail demand remains intact. [S1][S2]
Within standalone India, Home Care generated ₹1,329 crore, up 19%, while Personal Care generated ₹1,303 crore, up 8%. The two rounded categories total ₹2,632 crore versus the ₹2,631 crore standalone figure, a minor rounding difference. Management highlighted household-insecticide market-share gains despite weaker monsoon conditions and strong air-freshener demand. [S1][S2]
Indonesia sales reached ₹538 crore, up 20% both reported and in constant currency. The similar rates indicate little translation difference in this presentation's comparison. The country's operating EBITDA margin was 19.3%, and EBITDA grew 12%. Volume and product mix remain important because sales growth exceeded operating profit growth. [S2]
Africa, USA and Middle East generated ₹1,069 crore sales, up 40% reported and 23% constant currency. The large difference makes currency translation particularly relevant. Its operating EBITDA margin was 15.0%, and EBITDA grew 43% on the presentation's adjusted geographic basis. The profit growth is encouraging, but investors should not mistake currency-driven sales for recurring unit-volume growth. [S2]
Latin America and Others contributed ₹297 crore, with 43% reported and 28% constant-currency growth, but the presentation shows only a 0.9% operating EBITDA margin and an 85% decline in EBITDA. This is the clearest geographic warning: strong sales growth can coexist with weak earnings economics. [S2]
Business takeaways
Management discussed commodity inflation, particularly its effect on soaps and liquid detergents. It said calibrated pricing actions and cost savings would be used to protect margins while maintaining investment behind growth categories. A pricing action can help gross profit, but it can also test consumer demand if competitors do not follow or shoppers trade down. [S1]
The company retained its FY27 outlook for high-single-digit standalone underlying volume growth and double-digit consolidated revenue and EBITDA growth. These are management targets, not completed full-year results. The Q2 standalone volume rate of 7% is consistent with a high-single-digit ambition, but one quarter cannot establish the full-year outcome. [S1]
Analysts asked about improvements in digital advertising capability, execution discipline and household-insecticide product communication. Management described a programme of changes to advertising and sales execution. The investment test is whether those changes improve market share and product sales without requiring disproportionate spending. [S1]
Management also described household-insecticide market-share gains despite subdued monsoon conditions. This matters because weather can affect demand for insect-control products. Stronger market share in a difficult season could signal better product competitiveness, but investors should verify whether it persists when weather and competitive promotions change. [S1][S2]
Execution questions
Consumer-products companies typically need inventory, manufacturing capacity, distribution and brand investment. Godrej's reported 8% underlying volume growth increases the need to manage those resources efficiently. Yet the Q2 excerpts selected for this report do not provide a complete consolidated operating cash-flow statement or capital-expenditure bridge, so EBITDA should not be presented as free cash flow. [S1][S2]
The India trade-inventory correction is financially relevant. Management estimated a roughly 150-basis-point growth effect from reducing channel inventory. Cleaner distributor stock can reduce the risk of future returns or promotional discounting, but it may also temporarily lower company shipments. The next test is whether retail sales continue while channel inventory remains controlled. [S1]
Acquisition-related contingent consideration is another capital-allocation issue. The presentation identifies a ₹20 crore fair-value adjustment linked to the Muuchstac acquisition. Such an item can affect reported profit without representing a current-quarter cash operating expense. Investors should keep acquisition accounting separate from the profitability of selling consumer products. [S2]
The right capital-allocation questions are practical: are advertising and product launches improving sales productivity, is inventory aligned with consumer offtake, and do international businesses generate adequate cash after local costs? The evidence supports these questions but not a precise cash-return or debt-payback estimate.
Capital checkpoints
Bull case — volume growth and pricing restore operating leverage. India retains healthy underlying volume growth, home care maintains market-share gains, and measured pricing offsets commodity inflation. Indonesia continues to grow without margin deterioration, while Africa's underlying growth translates into cash profit. Consolidated EBITDA then has scope to grow faster than revenue. Confirmation would require an improved operating margin and consistent volume growth. [S1][S2]
Base case — sales grow faster than profit for a while. Consumer demand stays healthy, but commodity costs and investment in advertising limit near-term margin expansion. Currency translation continues to affect reported international growth, and the company balances price changes against consumer affordability. The business remains profitable, though the earnings multiple investors can justify depends on margin recovery.
Bear case — costs and execution erode the growth premium. Input costs stay high, price increases reduce volumes, or competitors take share. Weak weather or distribution changes hurt home-care demand, while Latin America remains low margin. International currency movements make headline growth look better than the underlying earnings trend. Strong revenue growth would then be a poor guide to shareholder returns.
Falsifiers
Action: WATCH for margin recovery alongside durable consumer demand. Godrej's Q2 result shows meaningful growth across several markets. The next quarter needs to show whether pricing, product mix and cost control can convert that growth into a stronger profit trajectory.
| Monitoring item | Q2 FY27 baseline | Next decision test |
|---|---|---|
| Consolidated sales | ₹4,396 crore | Volume and constant-currency growth |
| Consolidated underlying volume | 8% | Sustained consumer demand |
| Consolidated EBITDA growth | 12% | Catch-up with 19% sales growth |
| Reported PAT | ₹523 crore | Profit conversion |
| PAT excluding selected items | ₹532 crore | Repeatable earnings |
| Standalone India sales | ₹2,631 crore | Inventory correction and volume |
| Home Care | ₹1,329 crore | Market-share gains |
| Personal Care | ₹1,303 crore | Pricing and category mix |
| Indonesia | ₹538 crore | Margin alongside growth |
| Africa/USA/Middle East | ₹1,069 crore | Constant-currency growth and profit |
| Latin America/Others | 0.9% adjusted EBITDA margin | Meaningful margin recovery |
Next-quarter investor checklist
Specific limitations: The presentation provides adjusted geography operating EBITDA margins and a clear reported-to-exceptional-item PAT bridge, but the excerpts do not establish complete consolidated cash flow, current valuation inputs or a cash-based return on acquisition spending. The geography margin figures are adjusted for specified intercompany support and technical charges; they should not be presented as standalone statutory margins.
All financial amounts are ₹ crore unless stated otherwise. Reporting bases and management guidance are identified in context.
https://www.bseindia.com/xml-data/corpfiling/AttachLive/8bf1e6fa-d1b4-422f-bf06-7cdd37877e69.pdf
https://www.bseindia.com/xml-data/corpfiling/AttachLive/8bf1e6fa-d1b4-422f-bf06-7cdd37877e69.pdf
https://www.bseindia.com/xml-data/corpfiling/AttachLive/8bf1e6fa-d1b4-422f-bf06-7cdd37877e69.pdf
https://www.bseindia.com/xml-data/corpfiling/AttachLive/8bf1e6fa-d1b4-422f-bf06-7cdd37877e69.pdf
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.